Sangamo Therapeutics, Inc.
NASDAQ:SGMOBiotechnology
Healthcare
$0.18 +2.06%
+$0.00 today
- Market cap
- $70.43M
- Beta
- 1.29
- P/E (TTM)
- -0.5
- EPS (TTM)
- -$0.32
52W Low $0.10High $0.77
Volume 0.61M
Average 9.53M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$97.21M
FY 2025 · Annual
Investing Cash Flow
-$102,000.00
FY 2025 · Annual
Financing Cash Flow
$70.75M
FY 2025 · Annual
+149.3% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (178.3M) | (192.28M) | (257.83M) | (97.94M) | (122.93M) |
| Depreciation & Amortization | 17.64M | 20.56M | 22.19M | 9.36M | 7.6M |
| Deferred Income Tax | 2.77M | 0 | (6.34M) | 0 | 0 |
| Stock-Based Compensation | 32.96M | 31.65M | 27.36M | 12.38M | 9.08M |
| Change in Working Capital | (101.9M) | (82.32M) | (164.03M) | 4.51M | (4.22M) |
| Accounts Receivables | (789K) | 2.34M | (976K) | 953K | 155K |
| Inventory | 7.66M | 0 | 0 | 0 | 0 |
| Accounts Payables | (7.66M) | 13.35M | 5.59M | (14.17M) | 2.79M |
| Other Working Capital | (101.11M) | (98M) | (168.65M) | 17.72M | (7.17M) |
| Other Non-Cash Items | (6.43M) | (1.24M) | 153.8M | 4.55M | 13.27M |
| Operating Cash Flow | (233.25M) | (223.63M) | (224.84M) | (67.14M) | (97.21M) |
| Capital Expenditures | (23.28M) | (20.17M) | (21.16M) | (267K) | (102K) |
| Acquisitions (Net) | (119K) | (79.46M) | 0 | 1.95M | 0 |
| Purchases of Investments | (338.16M) | (277.39M) | (59.55M) | 0 | 0 |
| Sales of Investments | 609.76M | 356.85M | 234.24M | 35.84M | 0 |
| Other Investing Activities | 0 | 79.46M | 0 | 0 | 0 |
| Investing Cash Flow | 248.2M | 59.29M | 153.53M | 37.52M | (102K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 27.1M | 84.87M | 15.11M | 28.99M | 74.01M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.76M | (209K) | (518K) | (614K) | (3.26M) |
| Financing Cash Flow | 32.86M | 84.66M | 14.59M | 28.38M | 70.75M |
| Effect of Forex Changes | (263K) | 1.25M | 1.48M | (2.05M) | 4.09M |
| Net Change in Cash | 47.54M | (78.43M) | (55.24M) | (3.29M) | (22.47M) |
| Free Cash Flow | (256.53M) | (243.8M) | (246M) | (67.41M) | (97.31M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$122.9M
+ D&A$7.6M
+ Stock-Based Comp$9.1M
+ Deferred Tax$0
- Working Capital-$4.2M
+ Other Non-Cash$13.3M
= Operating Cash Flow-$97.2M
- Capex-$102.0K
= Free Cash Flow-$97.3M
Analysis
FY2025 free cash flow is -$97.3M. FCF conversion is 79.2% of net income. Operating cash flow was -$97.2M, with capex of -$102.0K. The largest bridge item is Other Non-Cash at $13.3M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | May 27, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 27, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 27, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 27, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 27, 2026 |
Does SGMO generate free cash flow?
Sangamo Therapeutics, Inc. (SGMO) generated -$97.31M of free cash flow in fiscal 2025.
How much operating cash flow does SGMO produce?
Operating cash flow was -$97.21M, before capital expenditures of $102,000.00.
Continue the stock analysis
Jump to another research area for this company.